IDO1 and head and neck squamous cell carcinoma: A 3.6‐fold (P = .1) increase seen in IDO expression in patients’ PBMCs during RT along with other protein mediators that promote immune suppression, suggesting RT could induce tolerogenic effects in HNSCC which can be targeted with checkpoint inhibitor therapy